This session, led by Dr. Lisa Larkin, provides a comprehensive review of the evolution of menopausal hormone therapy from the 1950s to the present. Attendees will examine the totality of evidence related to breast health and breast cancer risk, including data from the WHI and recent publications. The program will also address the implications of the FDA’s removal of the boxed warning on local and systemic MHT, the resulting shifts in public and media messaging, and practical approaches to counseling patients based on individualized risk profiles.

Lisa Larkin, MD, FACP, IF, MSCP is a nationally recognized women’s health internist and the founder of HERmedicine. With decades of clinical experience, Dr. Larkin has seen firsthand how gaps in evidence-based education impact both patients and clinicians. In addition to leading HERmedicine, she is the founder of Ms.Medicine and a longstanding advocate for advancing women’s healthcare. Her work is driven by a commitment to expanding access to reliable, comprehensive information and improving the quality of care delivered to women everywhere.